Recent Progress in the Development of Glucose Transporter (GLUT) Inhibitors
Journal of Medicinal Chemistry,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 2, 2025
Cancer
cells
exhibit
an
accelerated
glucose
uptake
and
glycolysis.
The
transmembrane
of
requires
specific
carrier
proteins,
such
as
transporters
(GLUTs)
sodium-coupled
cotransporters
(SGLTs).
GLUTs
transport
independently
the
energy
supply
have
become
promising
targets
for
cancer
therapy.
This
Perspective
mainly
focuses
on
current
research
progress
design
strategy
GLUT
inhibitors,
particularly
those
targeting
class
I
(GLUT1–4).
To
best
our
knowledge,
this
is
first
systematic
interpretation
progress,
opportunities,
challenges
faced
in
development
inhibitors
from
a
medicinal
chemistry
perspective.
We
hope
that
will
provide
insights
into
offering
feasible
approach
to
Язык: Английский
Current nano drug delivery systems for targeting head and neck squamous cell carcinoma microenvironment: a narrative review
Molecular Biology Reports,
Год журнала:
2025,
Номер
52(1)
Опубликована: Апрель 8, 2025
Язык: Английский
The Possibility of Plasma Membrane Transporters as Drug Targets in Oral Cancers
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(9), С. 4310 - 4310
Опубликована: Май 1, 2025
Plasma
membrane
transporters
are
increasingly
recognized
as
potential
drug
targets
for
oral
cancer,
particularly
squamous
cell
carcinoma
(OSCC).
These
play
crucial
roles
in
cancer
metabolism,
resistance,
and
the
tumor
microenvironment,
making
them
attractive
therapeutic
intervention.
Among
two
main
families
of
plasma
transporters,
ATP-binding
cassette
(ABC)
have
long
been
known
to
be
involved
efflux
contribute
chemoresistance
cells.
On
other
hand,
solute
carriers
(SLCs)
also
a
family
that
facilitate
transport
various
substrates,
including
nutrients
drugs,
recently
shown
chemosensitivity,
proliferation.
SLC
identified
biomarkers
targets,
their
expression
profiles
suggest
they
could
utilized
precision
oncology
approaches.
We
summarize
previous
reports
on
role
ABC
discuss
targets.
Язык: Английский
Fluorescence Imaging-Assessed Surgical Margin Detection in Head and Neck Oncology by Passive and Active Targeting
Molecular Diagnosis & Therapy,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 8, 2025
Surgery
remains
the
gold
standard
in
management
of
head
and
neck
squamous
cell
carcinoma
(HNSCC).
However,
anatomical
complexity
these
cancers,
combined
with
difficulty
discriminating
between
healthy
cancerous
tissue
detection
microlesions,
complicates
tumor
resection,
resulting
positive
surgical
margins,
which
are
associated
a
poor
patient
prognosis.
Fluorescence-guided
surgery
(FGS)
has
emerged
as
promising
technique
HNSCC,
improving
resection
margin
assessment.
FGS
strategies
can
be
roughly
divided
into
three
approaches;
namely,
natural
autofluorescence,
passive
delivery
fluorescent
contrast
agents,
active
targeting.
This
review
provides
comprehensive
overview
advances
made
particularly
aiming
to
improve
Recently,
field
shown
results
by
addressing
agents
targeted
overexpressed
epidermal
growth
factor
receptor
(EGFR),
both
preclinical
clinical
settings.
The
identification
new
targets
such
αVβ6
integrin,
uPAR,
PARP1,
so
on,
well
development
key
steps
further
making
it
an
essential
tool
precision
oncology.
Among
these,
was
demonstrated
studies,
integrin
is
emerging
target
due
its
high
specific
expression
margins.
Язык: Английский
Recent advances of photodiagnosis and treatment for head and neck squamous cell carcinoma
Neoplasia,
Год журнала:
2024,
Номер
60, С. 101118 - 101118
Опубликована: Дек. 24, 2024
Язык: Английский
The NXDC-MEN-301 Study on 5-ALA for Meningiomas Surgery: An Innovative Study Design for the Assessing the Benefit of Intra-Operative Fluorescence Imaging
Brain Sciences,
Год журнала:
2022,
Номер
12(8), С. 1044 - 1044
Опубликована: Авг. 6, 2022
5-aminolevulinic
acid
(5-ALA;
GleolanTM,
NX
Development
Corps.,
Lexington,
USA)
is
approved
for
fluorescence-guided
resections
of
suspected
malignant
gliomas.
Experience
has
demonstrated
that
meningiomas
also
show
fluorescence,
which
may
be
a
useful
surgical
adjunct.
We
present
an
innovative
design
multi-center,
prospective
study
to
determine
the
clinical
safety
and
potential
benefit
resection
with
utmost
bias
reduction.All
patients
meningioma
(all
grades)
receive
GleolanTM
20
mg/kg
2-4
h
prior
surgery
supported
by
fluorescence
excitation
from
blue
light
source
(Blue400,
Zeiss
Meditech,
Oberkochen,
Germany;
FL400,
Leica
Microsystems,
Heerbrugg,
Switzerland).
Surgeons
are
asked
whether
residual
tumor
can
observed
fluoresce
under
(BL)
after
no
longer
recognizable
using
conventional
illumination
at
end
surgery.
In
addition,
when
faced
tissues
uncertain
tissue
type
(so-called
"indeterminate"
tissue),
this
records
how
often
surgeons
make
correct
decision
based
on
influences
strategy.
The
primary
endpoint
percentage
in
whom
one
these
two
benefits
observed.
Other
endpoints
include
diagnostic
accuracy
compared
white
(WL)
versus
correlative
histology.
For
reduction,
pertinent
data
derived
videos
reviewed
independent
reviewers
blinded
surgeons'
assessments
status.
Data
will
included
approximately
100
participants
completing
15
centers
United
States,
Germany,
Austria.As
May
2022,
88
have
completed
study.
No
adverse
signal
been
detected.Preliminary
confirm
feasibility
our
design.
Accrual
targeted
completion
third
quarter
2022.
Язык: Английский
Unraveling the complexity of histone-arginine methyltransferase CARM1 in cancer: From underlying mechanisms to targeted therapeutics
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer,
Год журнала:
2023,
Номер
1878(4), С. 188916 - 188916
Опубликована: Май 15, 2023
Язык: Английский
A pH-sensitive supermolecular fluorescent probe for albumin-mediated cell imaging
XU Shao-hu,
Kai-Li Chang,
Xian-Ting Yan
и другие.
Tetrahedron,
Год журнала:
2023,
Номер
150, С. 133770 - 133770
Опубликована: Дек. 1, 2023
Язык: Английский
Clinical Experience with Autofluorescence Guided Oral Squamous Cell Carcinoma Surgery
Опубликована: Июнь 13, 2023
The
influence
of
preoperative
examination
oral
squamous
cell
carcinoma
(OSCC)
mucosal
surrounding
by
VELscope
(Visually
Enhanced
Lesion
Scope)
on
the
radicality
surgical
treatment
OSCC
was
goal
this
study.It
is
first
analysis
its
kind
with
a
total
number
122
patients
suffering
from
homogenous
distribution
different
tumor
stages
randomized
into
study
and
control
group
enrolled
in
our
after
meeting
inclusion
criteria.
checkup
accompanied
marking
range
loss
fluorescence
performed
before
surgery.
We
have
developed
unique
tattoo
technique
for
purpose.
pathohistological
results
treatment,
i.e.
margin
status,
were
then
compared.
achieved
pathological
free
(pFM)
55
patients,
close
(pCM)
6
cases
we
encountered
no
case
positive
(pPM)
layer
group.
In
comparison,
revealed
pPM
7
cases,
pCM
14
pFM
40
all
layer.
This
proved
that
autofluorescence
evaluation
can
enhance
ability
to
reach
resection.
Язык: Английский
Clinical Experience with Autofluorescence Guided Oral Squamous Cell Carcinoma Surgery
Diagnostics,
Год журнала:
2023,
Номер
13(20), С. 3161 - 3161
Опубликована: Окт. 10, 2023
In
our
study,
the
effect
of
use
autofluorescence
(Visually
Enhanced
Lesion
Scope—VELscope)
on
increasing
success
rate
surgical
treatment
in
oral
squamous
carcinoma
(OSCC)
was
investigated.
Our
hypothesis
tested
a
group
122
patients
suffering
from
OSCC,
randomized
into
study
and
control
enrolled
after
meeting
inclusion
criteria.
The
preoperative
checkup
via
VELscope,
accompanied
by
marking
range
loss
fluorescence
group,
performed
before
surgery.
We
developed
unique
mucosal
tattoo
technique
for
this
purpose.
histopathological
results
treatment,
i.e.,
margin
status,
were
then
compared.
we
achieved
pathological
free
(pFM)
55
patients,
close
(pCM)
6
cases,
encountered
no
cases
positive
(pPM)
layer.
comparison,
revealed
pPM
7
pCM
14
pFM
40
all
This
demonstrated
that
assessment
surroundings
OSCC
increased
ability
to
achieve
resection
4.8
times
terms
lateral
margins.
Язык: Английский